Provides for the initiation of treatment for COVID-19, influenza, and pharyngitis resulting from a Group A streptococcal infection by a licensed pharmacist in certain circumstances.
This bill would amend New York’s Education Law to expand the scope of pharmacy practice by allowing licensed pharmacists to initiate treatment for COVID-19, influenza, and pharyngitis caused by Group A streptococcal infection when a patient has a positive test result under an existing testing subdivision. The authority would operate under a statewide protocol developed by the Department of Health, which must address patient safety, recordkeeping, referral procedures, continuity of care, and reporting to the patient’s primary care or other health care provider. The bill also requires pharmacists to ask whether a patient has a regular provider and to maintain a local referral list for patients who do not.
The Department of Health would be required to maintain a searchable online list of primary care providers, including preferred providers such as patient-centered medical homes, federally qualified health centers, and providers serving Medicaid, low-income, uninsured, and disabled patients. The bill further requires pharmacists to keep records of the test result and treatment and to provide a report to the patient’s designated physician, physician assistant, or nurse practitioner unless the patient directs otherwise. The measure takes effect immediately and is temporary, expiring and being repealed on April 1, 2028.
The bill would temporarily broaden pharmacists’ authority under the Education Law by adding a new subdivision to section 6801, effectively creating a limited pharmacist-initiated treatment pathway for certain common infectious diseases. It would also impose new administrative duties on the Department of Health and pharmacists, including protocol development, provider directory maintenance, patient referral support, and documentation/reporting requirements. The measure affects pharmacists, patients seeking rapid treatment, primary care providers, and the Department of Health, while preserving physician oversight through reporting and referral provisions.
The bill’s sponsorship and structure suggest a generally supportive posture toward expanding access to timely treatment through pharmacists, especially for conditions that can be identified by testing and treated under standardized protocols. No committee transcript or vote record is available here, so there is no direct evidence of floor debate or recorded opposition. The inclusion of safeguards such as referral requirements, recordkeeping, and a sunset date indicates an effort to balance access with oversight and to make the expansion temporary and evaluative.
The main points of potential contention are likely to be the expansion of pharmacists’ scope of practice and the degree of clinical oversight involved. Supporters would likely emphasize improved access, convenience, and reduced burden on urgent care and primary care settings, while critics may raise concerns about patient safety, continuity of care, diagnostic accuracy, and whether pharmacists should initiate treatment for infectious diseases. The bill addresses some of those concerns by requiring a statewide protocol, referral pathways, and communication with the patient’s regular provider, but those same requirements may also be seen as administratively burdensome.